AI주식인사이트AI Stock Insight
B

에이비온

203400KOSDAQ자연과학 및 공학 연구개발업

57.8 / 100

Reference Date: 2026-06-10

Financial Score19.5 / 40
News Sentiment21.3 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but Revenue is on a declining trend. Plunged 44.2% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

ABION is a KOSDAQ-listed biopharmaceutical company specializing in the development of anti-cancer drugs and candidates based on companion diagnostics. Key pipelines include Vabametkib for non-small cell lung cancer, ABN101 (an interferon-beta-based antiviral), and ABN501 targeting Claudin3 protein in various cancers. Approximately 95.3% of its revenue comes from government research contracts.

Number of Employees

34people

Average Salary

72.5M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 62.704.0Point
PBR
1.77Industry Average 3.245.5Point

Lower than industry avg (good)

ROE
-60.24Industry Average -32.093.5Point

1.9x industry avg (good)

Debt Ratio
7.16Industry Average 7.314.0Point

In line with industry avg

Trend 2023~20252.5 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼12.3% (2-year basis)

Operating Profit Growth Rate
2.5 / 3

Avg ▲17.1% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -173.6% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 1,340Won52-week high 6,09152-week low 1,340
1-month return0.0Point

1m -44.17% (strong drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-08
  • Neutral주식등의대량보유상황보고서(약식)2026-05-26
  • Neutral주식등의대량보유상황보고서(일반)2026-05-22
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-22
  • Neutral분기보고서 (2026.03)2026-05-15